Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners
A survey of 86 German patient groups suggests pharma’s reputation is improving in the country that has been wary of pharma in the past, with Amgen and Janssen leading the way.
